IgNova GmbH   Report issue

For profit
Founded: Oberursel Germany (2013)
Status: Left NME R&D (2022)

Organization Overview

First Clinical Trial
2017
NCT03058224
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Indications

Overview

  • Highest Phase: Phase 0
  • # of Trials: 1
  • # of Trial APIs: 2